Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach

por Julian, Guilherme Silva, Rosim, Ricardo Papaléo, Carneseca, Estela Cristina, Rigolon, Jéssica
Publicado 2020